253 related articles for article (PubMed ID: 34879456)
1. Audio Interview: Waning Immunity against SARS-CoV-2.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Dec; 385(24):e99. PubMed ID: 34879456
[No Abstract] [Full Text] [Related]
2. Waning Immunity after the BNT162b2 Vaccine in Israel.
Goldberg Y; Mandel M; Bar-On YM; Bodenheimer O; Freedman L; Haas EJ; Milo R; Alroy-Preis S; Ash N; Huppert A
N Engl J Med; 2021 Dec; 385(24):e85. PubMed ID: 34706170
[TBL] [Abstract][Full Text] [Related]
3. Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection.
Nemet I; Kliker L; Lustig Y; Zuckerman N; Erster O; Cohen C; Kreiss Y; Alroy-Preis S; Regev-Yochay G; Mendelson E; Mandelboim M
N Engl J Med; 2022 Feb; 386(5):492-494. PubMed ID: 34965337
[No Abstract] [Full Text] [Related]
4. Audio Interview: New Evidence on SARS-CoV-2 Vaccine Boosters.
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Sep; 385(12):e48. PubMed ID: 34525292
[No Abstract] [Full Text] [Related]
5. Standardised neutralising antibody assays are needed for evaluating COVID-19 vaccines.
Wang Y
EBioMedicine; 2021 Nov; 73():103677. PubMed ID: 34742128
[No Abstract] [Full Text] [Related]
6. Audio Interview: Are Covid-19 Vaccine Boosters Necessary?
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Oct; 385(15):e63. PubMed ID: 34614335
[No Abstract] [Full Text] [Related]
7. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer.
Zeng C; Evans JP; Chakravarthy K; Qu P; Reisinger S; Song NJ; Rubinstein MP; Shields PG; Li Z; Liu SL
Cancer Cell; 2022 Feb; 40(2):117-119. PubMed ID: 34986328
[No Abstract] [Full Text] [Related]
8. Waning of SARS-CoV-2 booster viral-load reduction effectiveness.
Levine-Tiefenbrun M; Yelin I; Alapi H; Herzel E; Kuint J; Chodick G; Gazit S; Patalon T; Kishony R
Nat Commun; 2022 Mar; 13(1):1237. PubMed ID: 35246560
[TBL] [Abstract][Full Text] [Related]
9. Audio Interview: How Much Protection Does Prior SARS-CoV-2 Infection Provide?
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2021 Dec; 385(25):e100. PubMed ID: 34910868
[No Abstract] [Full Text] [Related]
10. Antibody titres before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in patients with cancer.
Debie Y; Vandamme T; Goossens ME; van Dam PA; Peeters M
Eur J Cancer; 2022 Mar; 163():177-179. PubMed ID: 35077960
[No Abstract] [Full Text] [Related]
11. SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
Falsey AR; Frenck RW; Walsh EE; Kitchin N; Absalon J; Gurtman A; Lockhart S; Bailey R; Swanson KA; Xu X; Koury K; Kalina W; Cooper D; Zou J; Xie X; Xia H; Türeci Ö; Lagkadinou E; Tompkins KR; Shi PY; Jansen KU; Şahin U; Dormitzer PR; Gruber WC
N Engl J Med; 2021 Oct; 385(17):1627-1629. PubMed ID: 34525276
[No Abstract] [Full Text] [Related]
12. Immunogenicity of BNT162b2 vaccine after two and three doses: Correspondence.
Daungsupawong H; Wiwanitkit V
Semergen; 2024; 50(4):102132. PubMed ID: 38295632
[No Abstract] [Full Text] [Related]
13. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose.
Kuhlmann C; Mayer CK; Claassen M; Maponga T; Burgers WA; Keeton R; Riou C; Sutherland AD; Suliman T; Shaw ML; Preiser W
Lancet; 2022 Feb; 399(10325):625-626. PubMed ID: 35063123
[No Abstract] [Full Text] [Related]
14. What the Omicron wave is revealing about human immunity.
Willyard C
Nature; 2022 Feb; 602(7895):22-25. PubMed ID: 35110764
[No Abstract] [Full Text] [Related]
15. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.
Levine-Tiefenbrun M; Yelin I; Alapi H; Katz R; Herzel E; Kuint J; Chodick G; Gazit S; Patalon T; Kishony R
Nat Med; 2021 Dec; 27(12):2108-2110. PubMed ID: 34728830
[TBL] [Abstract][Full Text] [Related]
16. Audio Interview: Can We Make More Effective Covid-19 Vaccines?
Rubin EJ; Baden LR; Morrissey S
N Engl J Med; 2022 Mar; 386(11):e36. PubMed ID: 35294821
[No Abstract] [Full Text] [Related]
17. Induction of robust cellular and humoral immunity against SARS-CoV-2 after a third dose of BNT162b2 vaccine in previously unresponsive older adults.
Romero-Olmedo AJ; Schulz AR; Hochstätter S; Das Gupta D; Virta I; Hirseland H; Staudenraus D; Camara B; Münch C; Hefter V; Sapre S; Krähling V; Müller-Kräuter H; Widera M; Mei HE; Keller C; Lohoff M
Nat Microbiol; 2022 Feb; 7(2):195-199. PubMed ID: 35013593
[TBL] [Abstract][Full Text] [Related]
18. Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination.
Normark J; Vikström L; Gwon YD; Persson IL; Edin A; Björsell T; Dernstedt A; Christ W; Tevell S; Evander M; Klingström J; Ahlm C; Forsell M
N Engl J Med; 2021 Sep; 385(11):1049-1051. PubMed ID: 34260850
[No Abstract] [Full Text] [Related]
19. Audio Interview: Addressing the Omicron Variant of SARS-CoV-2.
Rubin EJ; Baden LR; Barocas JA; Morrissey S
N Engl J Med; 2022 Jan; 386(4):e16. PubMed ID: 35081288
[No Abstract] [Full Text] [Related]
20. Comparative Effectiveness and Antibody Responses to Moderna and Pfizer-BioNTech COVID-19 Vaccines among Hospitalized Veterans - Five Veterans Affairs Medical Centers, United States, February 1-September 30, 2021.
Bajema KL; Dahl RM; Evener SL; Prill MM; Rodriguez-Barradas MC; Marconi VC; Beenhouwer DO; Holodniy M; Lucero-Obusan C; Brown ST; Tremarelli M; Epperson M; Mills L; Park SH; Rivera-Dominguez G; Morones RG; Ahmadi-Izadi G; Deovic R; Mendoza C; Jeong C; Schrag SJ; Meites E; Hall AJ; Kobayashi M; McMorrow M; Verani JR; Thornburg NJ; Surie D; ; ;
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1700-1705. PubMed ID: 34882654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
